Papers

Peer-reviewed International journal
Dec 20, 2019

Effect of rosuvastatin and eicosapentaenoic acid on neoatherosclerosis: the LINK-IT Trial.

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
  • Koji Kuroda
  • Hiromasa Otake
  • Masakazu Shinohara
  • Masaru Kuroda
  • Shigeyasu Tsuda
  • Takayoshi Toba
  • Yuichiro Nagano
  • Ryuji Toh
  • Tatsuro Ishida
  • Toshiro Shinke
  • Ken-Ichi Hirata
  • Display all

Volume
15
Number
12
First page
e1099-e1106
Last page
Language
English
Publishing type
Research paper (scientific journal)
DOI
10.4244/EIJ-D-18-01073

AIMS: We aimed to assess the effect of 10 mg/day of rosuvastatin plus eicosapentaenoic acid (EPA) versus 2.5 mg/day of rosuvastatin on the extent of neoatherosclerosis using optical coherence tomography (OCT). METHODS AND RESULTS: We randomly assigned 50 patients with non-obstructive neoatherosclerotic plaques detected on OCT to receive either rosuvastatin 10 mg/day and EPA 1,800 mg/day (intensive therapy group) or rosuvastatin 2.5 mg (standard therapy group). Follow-up OCT was performed one year later to evaluate serial changes in neoatherosclerosis. The serum low-density lipoprotein cholesterol (LDL-C) level decreased significantly from baseline to 12-month follow-up in the intensive therapy group (89 mg/dL to 70 mg/dL; p<0.001), while no change occurred in the standard therapy group. Lipid index change and percent changes in macrophage grade were significantly lower in the intensive therapy group than in the standard therapy group (-53.6 vs 310.1, p=0.001; -37.0% vs 35.3%, p<0.001; respectively). Percent changes in lipid index and macrophage grade were positively correlated with the changes in serum LDL-C and C-reactive protein levels, and negatively correlated with the change in serum EPA/arachidonic acid and 18-hydroxyeicosapentaenoic acid (EPA bioactive metabolite) level. CONCLUSIONS: Compared with rosuvastatin 2.5 mg/day, rosuvastatin 10 mg/day and EPA 1,800 mg/day significantly stabilised non-obstructive neoatherosclerotic plaques. CLINICAL TRIAL REGISTRATION: UMIN ID: UMIN000012576. https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000014711.

Link information
DOI
https://doi.org/10.4244/EIJ-D-18-01073
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/31334703
ID information
  • DOI : 10.4244/EIJ-D-18-01073
  • ISSN : 1774-024X
  • Pubmed ID : 31334703

Export
BibTeX RIS